1. Academic Validation
  2. Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities

Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities

  • J Med Chem. 2016 Jan 14;59(1):480-5. doi: 10.1021/acs.jmedchem.5b01426.
Derek C Medellin 1 Qiong Zhou 2 Robert Scott 1 R Matthew Hill 1 Sarah K Frail 3 Ramesh Dasari 1 Steven J Ontiveros 4 Stephen C Pelly 5 Willem A L van Otterlo 5 Tania Betancourt 1 6 Charles B Shuster 4 Ernest Hamel 7 Ruoli Bai 7 Daniel V LaBarbera 2 Snezna Rogelj 3 Liliya V Frolova 3 Alexander Kornienko 1
Affiliations

Affiliations

  • 1 Department of Chemistry and Biochemistry, Texas State University , San Marcos, Texas 78666, United States.
  • 2 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado 80045, United States.
  • 3 Departments of Chemistry and Biology, New Mexico Tech , Socorro, New Mexico 87801, United States.
  • 4 Department of Biology, New Mexico State University , Las Cruces, New Mexico 88003, United States.
  • 5 Department of Chemistry and Polymer Science, Stellenbosch University , Stellenbosch, Western Cape, South Africa.
  • 6 Materials Science, Engineering, and Commercialization Program, Texas State University , San Marcos, Texas 78666, United States.
  • 7 Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick National Laboratory of Cancer Research, National Institutes of Health, Frederick, Maryland 21702, United States.
Abstract

Docking studies of tubulin-targeting C2-substituted 7-deazahypoxanthine analogues of marine alkaloid rigidins led to the design and synthesis of compounds containing linear C2-substituents. The C2-alkynyl analogue was found to have double- to single-digit nanomolar antiproliferative IC50 values and showed statistically significant tumor size reduction in a colon Cancer mouse model at nontoxic concentrations. These results provide impetus and further guidance for the development of these rigidin analogues as Anticancer agents.

Figures
Products